In particular, more than 90% of pancreatic ductal adenocarcinomas have KRAS mutations, which indicates the essential incorporation of aberrations in the RAS signaling pathway in pancreatic cancer. This evidence concerns the gene KRAS and familial pancreatic carcinoma.